Proximal Ventures Closes $27.5M Debut Life Sciences AI Fund

A pharma executive can help a founder discover that the first product question was the wrong one. Proximal Ventures is building an investment practice around getting those conversations started early, including before incorporation, when changing the question still leaves room to change the company.

The San Francisco firm announced a $27.5M close for its debut Fund I on November 10, 2026, exceeding its $25M initial target. Founder and Managing Partner Sahir Raoof is backing pre-seed and seed companies applying AI to infrastructure across life sciences, with a mandate extending through drug discovery, development, manufacturing and commercialization.

For founders, the offer combines early capital with help approaching a complicated customer. For the pharmaceutical ecosystem, it puts a specialist investor behind the systems surrounding a medicine's progress to market, where technical ambition has to find a useful place in somebody else's work.

What Proximal Ventures Fund I will back

Proximal Ventures describes Fund I as a vehicle for AI-native life-sciences infrastructure. Its website lists checks of $500K-$1.5M and a pre-seed and seed focus, giving founders a more concrete starting point than a broad declaration of interest in healthcare AI. The firm also names supply chains and commercial execution among the areas where it wants to meet builders.

That scope matters because a drug-development business contains many different customers and decisions. A tool supporting discovery, a system helping a trial team and software used around manufacturing enter different working environments. Reading the mandate as permission to build for all of them at once would miss the practical value of specialization: choosing a sufficiently specific problem to understand deeply.

Morrison Foerster, which advised on the fund, corroborates the completed $27.5M debut close and the early-stage mandate. Proximal's release names Domino Lane, SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments and PagsGroup as strategic fund backers, alongside individual investors Nan Li and Zavain Dar. It does not disclose their commitment sizes.

The announcement concerns capital for the investment vehicle. Neither the close figure nor the website's check range tells a founder how much has already been invested, what future reserves look like or how a particular financing would be structured. Those questions belong in the conversation about the company and its needs.

Sahir Raoof brings the commercial question forward

Raoof's background helps explain why Proximal puts customer access inside its founding-stage offer. SignalFire's biography describes his work as the first commercial hire and VP of Business Development at Iterative Health, where he worked with biopharma partners and health systems. Earlier, he built biopharma research partnerships at Flatiron Health before moving into investment work at SignalFire.

The continuity is commercial rather than merely sectoral. Research partnerships require people to agree on what work is useful, which information can support it and how the relationship will operate. A founder approaching that environment benefits from discovering the customer's question while the product is still open to revision.

Proximal says it helps founders validate ideas, refine go-to-market strategy and connect with pharma executives, design partners and customers, sometimes before the company is incorporated. That timing gives its operating model a particular character. The investor can participate while the founder is deciding what deserves to become a business, instead of entering only after the company has written a polished account of itself.

For an engineer or scientist, an early discussion with a potential buyer can surface assumptions that a technical demonstration leaves untouched. The opportunity is to learn where the product fits and who would have to trust it. Proximal's disclosed support model makes those discussions part of its proposition without promising that an introduction will become a contract.

AI infrastructure has to fit the evidence around it

Raoof has been developing this investment view for some time. A 2025 SignalFire thesis he co-authored examined how AI could change pharmaceutical work historically handled through outsourced services. The argument locates opportunity in the work surrounding development, including the movement of information and decisions across organizations.

That is an investor's thesis about where new businesses can emerge. The practical question for a founder remains narrower: which task can a new company take responsibility for, and how will the customer assess whether it has been done well? A broad pharmaceutical mandate becomes commercially useful through a specific answer.

The FDA and European Medicines Agency's good-AI principles provide relevant context. They emphasize a defined context of use, multidisciplinary expertise, data governance, documentation and risk-based assessment. These are general principles for AI in drug development, with no endorsement of Proximal or its investments implied.

For an infrastructure founder, that context makes the person across the table consequential. The customer may help explain the evidence, oversight and working relationships a product will encounter. Bringing that understanding into the first product decisions can shape what the engineering team chooses to build, measure and explain.

Proximal's fund now gives Raoof a vehicle for making those early commitments across the life-sciences value chain. Its next useful exchange with a founder may concern a trial workflow, a manufacturing decision or a commercial process that has yet to become a product specification. The conversation can keep developing as the founder returns to the work with a better understanding of the person expected to use it.